<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref025">
 <label>25</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Foster</surname>
   <given-names>GR</given-names>
  </name>, 
  <name>
   <surname>Asselah</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Kopecky-Bromberg</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Lei</surname>
   <given-names>Y</given-names>
  </name>, 
  <name>
   <surname>Asatryan</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Trinh</surname>
   <given-names>R</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older</article-title>. 
  <source>PloS One</source>. 
  <year>2019</year>;
  <volume>14</volume>(
  <issue>1</issue>):
  <fpage>e0208506</fpage>
  <pub-id pub-id-type="doi">10.1371/journal.pone.0208506</pub-id>
  <?supplied-pmid 30601818?>
  <pub-id pub-id-type="pmid">30601818</pub-id>
 </mixed-citation>
</ref>
